Insight

Dec 16, 2024, 17:31

GemCis-NabPaclitaxel vs. GemCis in first line of advanced biliary tract cancers

Erman Akkus shared on X:

“GemCis-NabPaclitaxel vs. GemCis in 1L of advanced biliary tract cancers

SWOG S1815

No PFS or OS benefit

PFS benefit in gallbladder cancer subgroup.”

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Authors: Rachna T. Shroff, Gentry King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Imane El Dika, Benjamin Tan, Puneet Cheema, Anuj Patel, Renuka Iyer, R. Katie Kelley, Jaykumar Thumar, Anthony El-Khoueiry, Katherine A. Guthrie, E. Gabriela Chiorean, Howard Hochster, and Philip A. Philip.

GemCis-NabPaclitaxel vs. GemCis in first line of advanced biliary tract cancers

Aaron J. Scott Amit Mahipal Anthony El-Khoueiry Anuj Patel Aparna Kalyan Benjamin Tan cancer E. Gabriela Chiorean Erman Akkus Gentry King Howard Hochster Imane El Dika Jaykumar Thumar Katherine A. Guthrie Khalid Matin Laura Goff Milind M. Javle Mitesh J. Borad OncoDaily Oncology Philip A. Philip Puneet Cheema R. Katie Kelley Rachna T. Shroff Renuka Iyer Sarah Colby

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers